Global Blood Therapeutics CEO Ted Love's 2021 pay falls 53% to $8.2M
Global Blood Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 28, 2022
Global Blood Therapeutics reported fiscal year 2021 executive compensation information on April 28, 2022.
In 2021, five executives at Global Blood Therapeutics received on average a compensation package of $3.8M, a 54% decrease compared to previous year.
Average pay of disclosed executives at Global Blood Therapeutics
Ted W. Love, Chief Executive Officer, received $8.2M in total, which decreased by 53% compared to 2020. 46% of Love's compensation, or $3.8M, was in option awards. Love also received $343K in non-equity incentive plan, $716K in salary, $3.4M in stock awards, as well as $6K in other compensation.
For fiscal year 2021, the median employee pay was $345,973 at Global Blood Therapeutics. Therefore, the ratio of Ted W. Love's pay to the median employee pay was 24 to one.
Kim Smith-Whitley, EVP, Head of R&D, received a compensation package of $2.8M. 53% of the compensation package, or $1.5M, was in stock awards.
Jeffrey Farrow, Chief Financial Officer, earned $2.8M in 2021, a 54% decrease compared to previous year.
David Johnson, Chief Commercial Officer, received $2.7M in 2021, which decreases by 57% compared to 2020.
Jung Choi, Chief Business and Strategy Officer, earned $2.7M in 2021, a 54% decrease compared to previous year.
Related executives
Ted Love
Global Blood Therapeutics
Chief Executive Officer
Jeffrey Farrow
Global Blood Therapeutics
Chief Financial Officer
Jung Choi
Global Blood Therapeutics
Chief Business and Strategy Officer
David Johnson
Global Blood Therapeutics
Chief Commercial Officer
Kim Smith-Whitley
Global Blood Therapeutics
EVP, Head of R&D
You may also like
Source: SEC filing on April 28, 2022.